Maternal phenytoin administration affects DNA and protein synthesis in embryonic primary palates

Teratology
|December 1, 1983
PubMed

Insights

Phenytoin exposure during pregnancy significantly alters embryonic development. This study found phenytoin reduces DNA synthesis and increases protein synthesis in developing mouse palates and limb buds.

Area of Science:

  • Developmental Biology
  • Pharmacology
  • Teratology

Background:

  • Phenytoin (Dilantin) is an anticonvulsant medication.
  • Previous studies linked phenytoin to reduced embryonic primary palate growth in A/J mice.
  • The precise biochemical mechanisms underlying phenytoin's teratogenic effects require further investigation.

Purpose of the Study:

  • To investigate the biochemical and autoradiographic changes in embryonic primary palates and limb buds following phenytoin administration.
  • To correlate these changes with known morphological effects of phenytoin on palate development.

Main Methods:

  • Pregnant A/J mice were administered phenytoin (60 mg/kg) or vehicle on gestational day 10.
  • On gestational day 11, embryos received [3H]-thymidine (DNA synthesis) or [3H]-leucine (protein synthesis) via intraperitoneal injection.
  • Biochemical assays and autoradiography were performed on embryonic palates and limb buds one hour post-injection.

Main Results:

  • Phenytoin significantly reduced DNA synthesis in embryonic palates (3.8-fold decrease biochemically, 3-fold decrease autoradiographically).
  • Protein synthesis was significantly increased in embryonic palates from phenytoin-exposed embryos (2.6-fold increase biochemically, 2.2-fold increase autoradiographically).
  • Similar alterations in DNA and protein synthesis were observed in limb bud tissues.

Conclusions:

  • Phenytoin exposure alters nucleic acid and protein synthesis during critical periods of embryonic development.
  • These biochemical changes likely contribute to the observed morphological defects, such as reduced primary palate growth.
  • Further research is needed to fully elucidate the molecular pathways affected by phenytoin during embryogenesis.

Related Concept Videos

Genomic Imprinting and Inheritance02:30

Genomic Imprinting and Inheritance

Diploid organisms inherit genetic material through chromosomes from both parents. Copies of the same gene are known as alleles. In most cases, both alleles are simultaneously expressed and allow various cellular processes to function optimally. If one of the alleles is missing or mutated, the expression of the other allele can compensate; however, this is not true for all genes.
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...